focus -WSS

focus

author：explore 2025-09-29 16:35:00 - browse：78737

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： FDA warns J&J's Abiomed: We will regulate your software

explore

WSS

STAT Readout Newsletter: Today's biggest biotech updates

Senate committee scrutinizes Medicare Advantage brokers

Pharmacists can make shortage drugs, but at what cost?

STAT Summit: How a Chicago ER doctor tackles gun violence

First Opinion Podcast: Long Covid needs a new approach

Doctors are clamoring for more clarity on Paxlovid prescribing

explore

focus

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

'Brian's Song' at 50 still offers lessons about cancer for today

Alkermes shareholders re

Election results set back Medicaid expansion plans

United colonoscopy coverage change 'may cost lives,' doctors say

Researchers explore possible ties between long Covid, menopause

How one medical school became remarkably diverse

Trump used to be more articulate. What could explain the change?

Drug repurposing or repositioning? The language matters

How CRISPR works, explained in two minutes

leisure time

Restaurant meals are packed with calories, and we still keep eating them

Medicare reduced heart disease by changing how it pays doctors

The explosion of genetic testing requires a new approach

CEOs share strategies for surviving biotech slump

With heat waves through August, officials warn of health risks

Many breast cancer patients receive more radiation than needed

hotspot

explore

explore

hotspot